Identification of an antimalarial synthetic trioxolane drug development candidate
Jonathan L. Vennerstrom(University of Nebraska Medical Center), Sarah Arbe‐Barnes, Reto Brun(Swiss Tropical and Public Health Institute), Susan A. Charman(Monash University), Francis C. K. Chiu(Australian Regenerative Medicine Institute), Jacques Chollet(Swiss Tropical and Public Health Institute), Yuxiang Dong(University of Nebraska Medical Center), Arnulf Dorn(Roche (Switzerland)), Daniel Hunziker(Roche (Switzerland)), Hugues Matile(Roche (Switzerland)), Kylie A. McIntosh(Australian Regenerative Medicine Institute), Maniyan P. Padmanilayam(Nebraska Medical Center), Josefina Santo Tomas(Swiss Tropical and Public Health Institute), Christian Scheurer(Swiss Tropical and Public Health Institute), Bernard Scorneaux(Swiss Tropical and Public Health Institute), Yuanqing Tang(Nebraska Medical Center), Heinrich Urwyler(Basilea Pharmaceutica (Switzerland)), Sergio Wittlin(Swiss Tropical and Public Health Institute), William N. Charman(Monash University)
Cited by 617
Abstract
Related Papers
Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings 1PII of original article: S0169-409X(96)00423-1. The article was originally published in Advanced Drug Delivery Reviews 23 (1997) 3–25. 1
Christopher A. Lipinski, Franco Lombardo, Beryl W. Dominy et al.|Advanced Drug Delivery Reviews|2001|17.8k
Quantitative assessment of antimalarial activity in vitro by a semiautomated microdilution technique
R. E. Desjardins, Craig J. Canfield, J. David Haynes et al.|Antimicrobial Agents and Chemotherapy|1979|2.5k